Tudor Investment Corp ET AL Takes Position in AbCellera Biologics Inc. $ABCL

Tudor Investment Corp ET AL bought a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 730,122 shares of the company’s stock, valued at approximately $3,673,000.

A number of other large investors have also added to or reduced their stakes in the company. Baillie Gifford & Co. increased its stake in AbCellera Biologics by 0.6% during the 3rd quarter. Baillie Gifford & Co. now owns 10,422,966 shares of the company’s stock worth $52,428,000 after buying an additional 62,962 shares during the period. Two Sigma Investments LP boosted its position in AbCellera Biologics by 25.9% in the 3rd quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company’s stock valued at $26,031,000 after buying an additional 1,064,290 shares during the last quarter. Bank of America Corp DE grew its stake in shares of AbCellera Biologics by 977.8% during the third quarter. Bank of America Corp DE now owns 2,418,304 shares of the company’s stock valued at $12,164,000 after acquiring an additional 2,193,939 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of AbCellera Biologics during the third quarter worth about $3,707,000. Finally, Jump Financial LLC purchased a new stake in shares of AbCellera Biologics during the third quarter worth about $3,398,000. 61.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABCL has been the subject of a number of analyst reports. Wall Street Zen raised AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.75.

AbCellera Biologics Price Performance

NASDAQ ABCL opened at $3.35 on Friday. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -6.84 and a beta of 0.84. AbCellera Biologics Inc. has a 12 month low of $1.89 and a 12 month high of $6.51. The company’s fifty day moving average price is $3.52 and its two-hundred day moving average price is $4.11.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.15. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. The business had revenue of $44.85 million for the quarter, compared to analyst estimates of $6.31 million. As a group, analysts anticipate that AbCellera Biologics Inc. will post -0.59 EPS for the current year.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.